FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 212 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not... March 1, 2021 New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... December 7, 2020 Research with integrity – all the fun of the FAIR August 8, 2023 Advancing Cancer Research as a Married Couple: “Your Stories” Podcast December 18, 2020 Load more HOT NEWS Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... Is CBD Safe for People With Cancer?
